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Abstract
The loss of p53 function is a central event in the genesis of osteosarcoma (OS). How mutation of p53 enables OS
development from osteoblastic lineage cells is poorly understood. We and others have reported a key role for elevated
and persistent activation of the cAMP/PKA/Creb1 pathway in maintenance of OS. In view of the osteoblast lineage
being the cell of origin of OS, we sought to determine how these pathways interact within the context of the normal
osteoblast. Normal osteoblasts (p53 WT) rapidly underwent apoptosis in response to acute elevation of cAMP levels
or activity, whereas p53-deﬁcient osteoblasts tolerated this aberrant cAMP/Creb level and activity. Using the p53
activating small-molecule Nutlin-3a and cAMP/Creb1 activator forskolin, we addressed the question of how p53
responds to the activation of cAMP. We observed that p53 acts dominantly to protect cells from excessive cAMP
accumulation. We identify a Creb1-Cbp complex that functions together with and interacts with p53. Finally,
translating these results we ﬁnd that a selective small-molecule inhibitor of the Creb1-Cbp interaction demonstrates
selective toxicity to OS cells where this pathway is constitutively active. This highlights the cAMP/Creb axis as a
potentially actionable therapeutic vulnerability in p53-deﬁcient tumors such as OS. These results deﬁne a mechanism
through which p53 protects normal osteoblasts from excessive or abnormal cAMP accumulation, which becomes
fundamentally compromised in OS.
Introduction
Osteosarcoma (OS) is the most common cancer of bone
and primarily affects teenagers and young adults. Whilst
our understanding of the genetics of OS have rapidly
advanced, clinical outcomes have stagnated for several
decades. OS is a cancer with many complex genetic
abnormalities, but few genetic drivers. Conventional
human OS has very high, to near universal, rates of TRP53
mutation with recurrent mutations of RB1, ATRX, and
DLG2 in 29–53% of cases1–3. Genome-wide association
studies (GWAS) and sequencing studies have identiﬁed
mutations in key components of the cAMP pathway
within the mutational spectrum of human OS4,5. Several
recent studies in murine models have provided further
evidence for involvement of the cAMP-PKA pathway
in OS6–9, but how these pathways interact in the normal
osteoblasts has not been resolved.
During normal bone development, osteoblastic lineage
cells communicate, regulate, and activate each other
through the secretion of speciﬁc molecules including
parathyroid hormone-related protein (PTHrP). PTHrP
acts through its cell surface receptor PTHR1, with evi-
dence also for an intracrine action10,11. Osteoblast-speciﬁc
ablation of Pthrp in mice resulted in impaired bone for-
mation both in vivo and ex vivo12,13. These ﬁndings
identiﬁed a central role for osteoblast lineage generated
PTHrP in the physiological regulation of bone formation.
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This paracrine role was later extended when PTHrP
production by osteocytes was found to be necessary for
normal bone formation and strength14. As osteoblastic
cells commit to form mature osteoblasts and ultimately
osteocytes, PTHR1 expression increases and so does sig-
naling via PTHrP14. PTHR1/PTHrP acts primarily to
activate adenylyl cyclase and stimulate cAMP produc-
tion15. Primary tumor cell cultures from mouse models of
OS demonstrate both elevated and persistently active
cAMP signaling, signiﬁcantly contributed to by an auto-
crine PTHR1-PTHrP loop6,8,16.
Inactivating TRP53 mutations are one of the most
common mutations in human cancer17. The most fre-
quent mutation type is point mutation resulting in P53
proteins with altered function18. Unlike most cancers, in
OS unique genomic rearrangements and other mutation
types often result in null alleles of TRP531,3, and TRP53 is
the most recurrently mutated gene in OS1. TRP53
mutations are also hallmark of the hereditary cancer
predisposition disorder Li-Fraumeni syndrome3,7,19,20,
and Tp53 knockout mice develop OS at high penetrance
amongst other tumors21,22. P53 is activated upon geno-
toxic or oncogenic stress and regulates cell cycle, survival,
and apoptosis23–29. P53 also regulates “non-canonical”
programs such as differentiation, autophagy, metabolism,
cellular pluripotency, and plasticity30. P53 can mediate
its non-canonical action via its interaction with a large
number of transcription factors and coactivators31. Of
relevance to OS, P53 regulates osteoblastic differentiation
and Tp53−/− mice have altered osteoblast differentiation
and a high bone mass phenotype32.
In osteoblastic cells, activation of the cAMP pathway
ultimately leads to activation of the transcription factor
Creb1. Creb1 activates transcription of many cellular
genes in response to cAMP. Numerous reports describe
the role of CREB1 in malignancies such as AML, prostate
cancer and other solid tumors including OS8,33–35. When
phosphorylated on serine 133, CREB1 can facilitate the
interaction between CBP and P53 on P53-responsive
promoters36. We recently described the interaction of
the cAMP/Creb1 pathway with p53 deletion in the
maintenance of OS8. Herein, we have explored the
interaction between these pathways in normal osteoblasts.
We ﬁnd that p53 normally acts to protect osteoblasts
from aberrantly elevated cAMP/Creb activity, and that
activation of this pathway can be tolerated once p53 is
lost. Moreover, this dependence reveals a new therapeutic
vulnerability in OS cells.
Materials and methods
Study approval
All animal experiments were approved by the AEC
(AEC#030/14 and AEC#031/15; St. Vincent’s Hospital,
Melbourne).
Animals and cell culture
Long-bone primary osteoblastic cells and mouse OS cell
cultures were cultured in αMEM (Lonza), 10% non-heat
inactivated FBS (SAFC Biosciences) and 1% Penicillin/
Streptomycin/Glutamine (Life Technologies). OS cell
cultures were derived by mincing tumor tissue with a
scalpel. The resulting tumor cells were transferred to
a 6 well plate and allowed to establish in standard culture
conditions. Primary cultures were passaged at 60–80%
conﬂuence with media changes every 2–3 days. The pri-
mary osteoblastic cells were derived from long-bone tis-
sue, cleaned, and crushed lightly with a mortar-pestle.
The suspension was rinsed with PBS, ﬁltered to remove
the majority of the hematopoietic (solution was clear).
The bone fragments were placed in 15ml of collagenase
I (3 mg/ml) (Worthington), and incubated in a shaking
37 °C water bath for 45min. A volume of 35ml of
PBS/2% FBS was then added and the cell suspension
was sieved. The resulting population of long-bone
derived cells was centrifuged at 400× g for 5 min, the
cells were resuspended in culture media and plated onto
a 6-well plate. On the next day, the 6-well plate was
washed with PBS before adding fresh culture media to
remove ﬂoating debris. At 48 h post-derivation, the cells
were used for experiments.
Generation of isogenic p53WT/WT and p53KO/KO normal
osteoblastic cells
For experiments involving R26-CreERT2ki/+p53ﬂ/ﬂ, pri-
mary osteoblasts were isolated from long bones using
collagenase digestion protocol as above. After 48 h the
cells were split into two separate T25cm2 ﬂask containing
α-MEM (Lonza, Basel, Switzerland) supplemented with
10% fetal bovine serum (Sigma, St. Louis, MO, USA; non-
heat inactivated), 2 mM Glutamax (Life Technologies,
Carlsbad, CA, USA). The cells were treated with and
without 500 nM 4-hydroxy-tamoxifen (Merck Millipore)
to induce CRE activity and deletion of p53 over 21 days.
Deletion of p53 was conﬁrmed by genomic DNA PCR
and western blotting in the KO cultures treated with
tamoxifen, compared to non-tamoxifen treated isogenic
R26-CreERT2ki/+p53ﬂ/ﬂ cultures. Three independently
derived R26-CreERT2ki/+p53ﬂ/ﬂ cultures were generated
and used for experiments.
OS cells
Primary mouse OS cell cultures were derived from
primary tumors from murine models of ﬁbroblastic
OS (Osx-Cre p53ﬂ/ﬂpRbﬂ/ﬂ) or osteoblastic OS (Osx-
Cre Tgshp53.1224pRbﬂ/ﬂ) and were maintained and
studied for less than 15 passages16,22. All cells used
were obtained directly from mouse models of OS, no
further authentication performed by the authors, myco-
plasma negative.
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In vitro differentiation of p53WT/WT and p53KO/KO cells
Three independently derived p53WT/WT and p53KO/KO
cells were seeded at 3000 cells/cm2 on 6-well plates in α-
MEM with 10% FBS three days prior to differentiation
induction. When cells had reached 100% conﬂuence (Day
0), control cells were harvested, and all other cells were
replenished three times per week with osteoblastic dif-
ferentiation media: α-MEM (Lonza), 10% (v/v) FBS, 25
mM HEPES, 1% (v/v) (Gibco), Penicillin-Streptomycin
(Gibco), 2 mM GlutaMAX™ (Gibco), 50 μg/ml ascorbate
(Sigma), 0.01M β-glycerophosphate (Sigma).
IBMX treatment and cAMP assays
p53WT/WT and p53KO/KO cells were seeded at 1.0 × 105
cells on 6-well plates in α-MEM with 10% FBS 1 day prior
to IBMX treatment. 1 mM IBMX was added to the
medium and the cells were incubated for 1 h before taking
images. The cells were further incubated for 16–18 h
before extracting lysates for western blotting. cAMP assay
was performed as described previously6,8.
Radioimmunoassay (RIA) for PTHrP
After the cells became conﬂuent, fresh α-MEM (Lonza),
10% (v/v) FBS, 25 mM HEPES, 1% Penicillin-
Streptomycin (Gibco), 2 mM GlutaMAX™ (Gibco). The
medium was aspirated and the cells were washed once
with PBS. RIA was carried out using polyclonal goat
antiserum raised in goats against PTHrP(1–40), using
recombinant PTHrP(1–84) as standard6. The sensitivity
of this assay is 2pmol/l.
PI staining
Adherent cells were washed in PBS, trypsinised, and
pooled with the dead population of the same well. The
cells were counted, resuspended in PBS and approxi-
mately 500,000 cells were transferred to a V-bottom plate.
The plate was centrifuged, the cell pellet was dispersed
and 100–150 μl of −20 °C chilled Ethanol was added to
the cells. After brief incubation on ice, cells were pelleted,
the ethanol was removed, and the cells were washed in
PBS. Finally, the cells were resuspended in 100 μl PBS
containing 40 μg/ml PI (Sigma-Aldrich, MO, USA) and
40 μg/ml RNAseA (Qiagen). Following PI addition, the
cells were incubated in the dark for 30–60min at 37 °C
and analysed using a Fortessa FACS analyser (BD). The
data were further analysed using ﬂow cytometry analysis
software FlowJo and the DNA cycles were determined
using software Modﬁt LtTM.
Plasmids and constructs
Two independent p53WT/WT cell lines were used for
overexpressing pLenti6/V5-p53_wt p53 construct, a gift
from Bernard Futscher (Addgene plasmid # 2294537).
Lentiviral packaging vector psPax2 (plasmid #12260) was
obtained from Addgene (Cambridge, MA, USA), the
pCMV-Eco Envelope (Cat No. RV112) vector was pur-
chased from Cell Biolabs (San Diego, CA, USA). Two
independent isogenic p53WT/WT cell lines were infected
with lentivirus overexpressing human V5 tagged-P53.
After 48 h cells were selected with 10 µg/ml Blasticidine S.
The cells were conﬁrmed for overexpression of WT V5-
p53 by western blot analysis and used for experiments.
For the construction of plasmid encoding a mouse p53
transcript, a cDNA encoding the mouse p53 transcript
(IDT DNA) was cloned in pLVX vector (Clontech). Three
independent Trp53WT/WT cell lines were used for over-
expressing pLVX-p53_wt p53 construct. The cells were
conﬁrmed for overexpression of p53 by western blot
analysis and qPCR and used for experiments.
Flow cytometry
Three independent isogenic p53WT/WT and p53KO/KO
cell lines were prepared by trypsinization. Antibodies
against murine CD45, Mac1, Gr1, F4/80, B220, IgM, CD2,
CD3, CD4, CD8, Ter119, Sca1, CD51, PDGFRα (CD140a),
CD31, either biotinylated or conjugated with eF450, PE,
PerCP-Cy5.5, or APC were obtained from eBioscience
(San Diego, CA) or BD Pharmingen. Biotinylated anti-
bodies were detected with Streptavidin-Qdot605 (Invi-
trogen). Flow cytometry was performed on an LSRII
Fortessa (BD Bioscience) interfaced with Cell Quest
software, data were analysed on FlowJo (TreeStar).
Annexin V and 7AAD staining
Three independent isogenic p53WT/WT and p53KO/KO
cell lines were treated with 1 mM IBMX and 10 µM
Forskolin for 1 h and 24 h, respectively. Cells were washed
and collected after trypsinization and then stained in
1× Annexin Binding buffer (eBioscience) diluted 1:20
with Annexin V-APC (1 mg/ml) (eBioscience) and
7-Aminoactinomycin D (7AAD) (100 μg/ml) (Life Tech-
nologies) for 15 min. Following the addition of 4 volumes
of 1× Annexin Binding buffer, apoptotic cells were
detected and quantiﬁed using FACS (LSRFortessa). Live
cells (Annexin V negative, 7AAD low) and cells in early
and late stages of apoptosis (Annexin V positive, 7AAD
low/high) were quantiﬁed.
RNA extraction, cDNA synthesis and Quantitative realtime
PCR (QPCR)
RNA was extracted using RNA extraction kits with on-
column DNase digestion (Qiagen, Limburg, Netherlands;
Bioline, London, UK) or TriSure reagent (Bioline). cDNA
was synthesised from total RNA using a Tetro cDNA
synthesis kit (Bioline) or AfﬁnityScript cDNA synthesis kit
(Agilent Technologies, Santa Clara, CA, USA). Gene
expression was quantiﬁed on a Stratagene Mx3000P
QPCR system (Agilent) using Brilliant II SYBR green
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QPCR master mix (Agilent) with primers speciﬁc to genes
of interest (Primer sequences in Table S1). Relative
expression was quantiﬁed using the comparative CT
method (2-(Gene Ct – Normalizer Ct)). Samples were ampliﬁed
in duplicate.
Western blotting
Protein lysates were prepared in RIPA buffer (50 mM
Tris-HCl pH7.4, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 150mM NaCl, 2 mM EDTA, 50 mM NaF).
Protein (10–25 µg) was electrophoresed on 10% Bis Tris
or 4–12% Bis-Tris gradient NuPAGE Novex protein gels
(Life Technologies) and transferred to PVDF membrane
(Merck Millipore, Billerica, MA, USA). Membranes were
blocked in 5% skim milk in TBST (20 mM Tris, 150mM
NaCl, 0.1% Tween-20) for 1 h before incubation with
primary antibodies diluted in 5% skim milk in TBST
overnight a 4 °C, or for 1 h at room temperature in the
case of pan-ACTIN. All antibodies, p53 (1C12; Cell Sig-
naling 2524), Phospho-CREB ((Ser133) Cell Signaling
Technologies, #9198), Anti-CREB1 ChIP grade (ab31387),
and CBP (C-1, Santa Cruz, sc-7300) were used at 1:2000,
except pan-actin (Ab-5, Thermo Scientiﬁc, Waltham,
MA, USA) that was used at 1:3000. Cleaved caspase
3 Asp175 [5A1E] was from Cell Signaling Technologies
9664 S. Following four 10min washes with TBST, mem-
branes were exposed to ECL Prime (GE Healthcare Life
Sciences, Piscataway, NJ, USA) and exposed to X-ray ﬁlm
to detect the expression levels of proteins.
Immunoprecipitation
1 × 106 cells for each subtype (Three independent iso-
genic p53WT/WT and p53KO/KO) were seeded and allowed
to proliferate for 24 h. p53WT/WT and p53KO/KO cells were
treated with less than 0.1% DMSO, 10 µM forskolin or
100 nM doxorubicin and in combination. Cells were also
treated with 0.1% DMSO, 10 µM forskolin or 10 µM
Nutlin and in combination). Post treatment the cells were
scraped on ice cold PBS and snap frozen until further use.
For immunoprecipitation, non-ionic lysis buffer contain-
ing 1% NP-40, Tris-HCl at pH8.0, 137mM NaCl and 2
mM EDTA with protease inhibitors (Roche, Burlington,
NC, USA) was used. 2–3 × 106 million cells were lysed in
non-ionic lysis buffer and left on ice for 30min, and the
cells were further sonicated using a UCD-200 Bioruptor
(Diagnenode, Denville, NJ, USA) on high at 4 °C for a total
shearing time of 2 min (60 min of 10 s on and 50 s off).
Cell debris was cleared by centrifugation at 13,000 rpm for
10min at 4 °C and supernatants were diluted 10-fold in
1:10 diluted non-ionic lysis buffer. After removing 1%
input for the total number of cells of each sample as an
input control, samples were incubated with either 2 µg
CREB1 antibody (Abcam: ab31387), 2 µg of phospho-
CREB1 antibody (Cell Signaling: 9198), 2 µg of p53
antibody (1C12, Cell Signaling 2524), 2 µg of CBP (C-1,
Santa Cruz: sc-7300) and 2 µg of control rabbit IgG
(Merck Millipore), or no antibody overnight at 4 °C with
rotation. Complexes were collected for 1 h at 4 °C with
rotation with 60 µl of protein A sepharose beads (Invi-
trogen) that had been pre-equilibrated in 1:10 Non-Ionic
lysis buffer for 1 h. Beads were washed one time each with
Low Salt buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20mM Tris-HCl pH8.1, 150mM NaCl), High Salt
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20mM
Tris-HCl pH8.1, 500 mM NaCl) and LiCl buffer (0.25M
LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA, 10mM
Tris-HCl pH8.1), followed by two washes with TE buffer.
Protein-Protein complexes were eluted from the beads
adding 30 μL of 4X Laemilli buffer. The samples were
ready for western blot analysis.
CREB-CBP inhibitor treatment
p53WT/WT and p53KO/KO cells and the corresponding OS
cells derived from cell lines made from primary tumors
were plated at 2500 cells per well in 96-well plates.
After 24 h, the cells were treated with 666–15 (Tocris
Bioscience) in an 11-point dose response ranging from
0.01 to 10mmol/L. All assays were performed in dupli-
cate. At 48 and 72 h after treatment, the cell viability
for each well was quantiﬁed on the basis of the direct
measurement of intracellular ATP using the ATP-Lite
luminescent assay (PerkinElmer). All luminescent mea-
surements were recorded on the EnSpire plate reader
(PerkinElmer). Data were plotted and the IC50 value
calculated using Prism 6 software.
Bioinformatics and data mining and selection of target
genes
Creb1 target genes were selected from38–40. We only
validated genes which were considered related to cAMP
signaling. For validation of p53 direct targets we referred
to41 that describes a genome-wide approach to detect lnc-
RNAs and p53 transcriptional targets in human cells. We
downloaded the ChIP-seq data for p53 in MEFs from42.
We therefore compared the human p53 ChIP-seq data
with previously published p53 ChIP-seq data from mouse
embryonic ﬁbroblasts (MEFs) treated with the DNA-
damage drug doxorubicin. A subset of genes which were
doxorubicin induced and were common in human and
mouse datasets were selected.
Statistical analysis
Data were presented as mean ± SEM. Statistical com-
parisons were performed in Prism 6.0 unless otherwise
indicated. Parametric Student’s t-test, area under the
curve or 2-way ANOVA with multiple comparison test
were used for comparisons with P < 0.05 considered as
signiﬁcant.
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Fig. 1 (See legend on next page.)
Walia et al. Cell Death and Disease  (2018) 9:844 Page 5 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
Results
Acute loss of p53 in primary osteoblasts activates PTHrP-
cAMP-Creb1 signalling
We modelled the acute loss of p53, in isolation of other
genetic changes, using primary osteoblastic cells isolated
from long bones of R26-CreERT2ki/+Tp53ﬂ/ﬂ (referred to
as KO herein) and R26-CreERT2ki/+Tp53+/+ (referred to
as WT) animals. Cells were isolated and expanded for
5–7 days. The cells were then cultured in proliferative
media and treated+ /− tamoxifen to generate isogenic
cultures. Tamoxifen treatment was continued until day 21
when it was stopped. The cells were genotyped to conﬁrm
they were wild-type or Tp53-deﬁcient then used for
the assays described. For all subsequent experiments,
excluding those describing results from differentiation
cultures, the cells were plated and allowed to reach
~70–80% conﬂuence then used for experiments (for
example, treated with IBMX or forskolin). For differ-
entiation experiments, the cells were plated at the
appropriate cell density (no tamoxifen added) and placed
in differentiation inducing media for a further 21 days.
Isogenic cell pairs (Tp53 WT and Tp53 KO) were made
in order to allow comparison of cells from the same
animal (Fig. 1a).
Analysis of proliferative cultures immediately after
cessation of tamoxifen treatment demonstrated that the
expression of p53 target genes was diminished in the KO
cultures, compared to non-tamoxifen treated isogenic
cultures8. By cell surface phenotype, expression of CD51
was increased and Sca1 was decreased on KO cells com-
pared to WT counterparts (Fig. 1b, c). At the completion
of tamoxifen treatment, when deletion of p53 was con-
ﬁrmed, there was increased expression of Osterix, Pthrp,
and Sost in KO cells, with no signiﬁcant increase in other
osteoblast lineage markers Pthr1 and Runx2 (Fig. 1d). A
clearer indication of the effect of Tp53 deﬁciency was
obtained by examining differentiation potential of the
WT and Tp53 deleted cells by culturing for a further
21 days in osteogenic differentiation media. Expression
of osteoblastic lineage markers remained stable in the
KO cells and generally at a higher level than in the p53
WT cells during differentiation (Supplemental Fig. 1A, B).
Adipogenic markers Pparg and Adiponectin changed
comparably between genotypes (Supplemental Fig. 1A, B).
These ﬁndings are consistent with previous reports
that p53 loss is associated with altered osteoblast
differentiation32,43.
We assessed the effect of Tp53 deﬁciency on PTHrP-
cAMP-Creb1 pathway status. KO cells had increased
PTHrP protein levels and intracellular cAMP accumula-
tion compared to p53 WT counterparts (Fig. 1e, f).
Consistent with these ﬁndings, there were higher levels
of basal phospho-Creb1 in p53-deﬁcient cells (Fig. 1g).
Examination of the kinetics of p53 protein expression
during differentiation revealed that in WT cells, p53
protein level gradually reduced, concurrent with a
reduction of Creb1 (Supplemental Fig. 1C, D). However,
p53-deﬁcient osteoblasts retained Creb1 expression over
the differentiation time course, including phosphorylated
active Creb1 (Supplemental Fig. 1C, D). This result is
consistent with the persistence of Creb1 and phospho-
Creb1 in OS cells induced to differentiate in vitro8.
Elevated cAMP induces apoptosis that is regulated by p53
As intracellular cAMP accumulation increased after
p53 deletion from primary osteoblasts (Fig. 1f), we sought
to determine the effect of acutely elevating cAMP levels
on wild type osteoblastic cells. The cells were treated
with DMSO (control) or IBMX (1mM), which inhibits
the phosphodiesterases (PDE) that degrade cAMP, to
enable accumulation of the cells’ intrinsic cAMP. Within
1 h of IBMX treatment there was a major difference in
cell morphology, with WT cells poorly attached to the
culture dish compared to the KO (Fig. 2a). There was a
signiﬁcant increase in AnnexinV positive cells in the WT
culture (Fig. 2b, c). Cell death/apoptosis was assessed
by measuring the levels of cleaved caspase-344. Upon
preventing breakdown of intracellular cAMP, cleavage
of caspase-3 was rapidly induced in WT cells unlike
the KO counterpart (Fig. 2d).
As an alternative approach to persistently elevate
cAMP, cells were treated with the direct cAMP stimulus
forskolin (Supplemental Figure 2A). After 24 h of for-
skolin treatment, p53 WT cells had an altered morphol-
ogy similar to the IBMX-treated cells (data not shown).
WT cells underwent cell death within 24 -hours of
(see ﬁgure on previous page)
Fig. 1 Loss of p53 in primary osteoblasts leads to accelerated differentiation and increased PTHrP-cAMP-Creb1 axis. a Schematic
representation of generation of independent p53WT/WT and p53KO/KO cells. b p53WT/WT and p53KO/KO cells assessed for expression of Sca-1, CD51,
representative results shown, n= 3 independent experiments. c Cell surface markers from each cell line (n= 3 independent cultures). d mRNA for
Osterix, Runx2, Pthr1, Pthlh, Osteocalcin, Sost, Pparg, Adiponectin by qPCR in p53 WT and p53 KO cells (normalized to β2m; mean ± SEM, n= 3). e PTHrP
in lysates of p53WT/WT and p53KO/KO; pmol/µg of protein using radioimmunoassay. Data pooled from 3 independent cultures; mean ± SEM. f cAMP
accumulation (pmol/µg of protein) after treatment with 100 μM IBMX for 30 mins in p53WT/WT and p53KO/KO. Data pooled from 3 independent
cultures; mean ± SEM. g Western blot of p53, pCREB1, and Creb1, β-Actin used as a loading control. Data representative of 2 independent cell lines
from each. See Figure S1. For all panels: *P < 0.05, **P < 0.01, ***P < 0.001
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forskolin treatment as quantitated by AnnexinV/7AAD
staining (Fig. 2e, f). Elevation of cAMP via forskolin
resulted in increased phosphorylation of Creb1, as
expected, and also of p53 (Fig. 2g). p53 KO cells were
protected from cell death induced by forskolin treatment
(Fig. 2h, i). This occurred despite the p53 KO cells gen-
erating higher intracellular cAMP levels from the same
dose of forskolin than the WT cells (Supplemental
Figure 2A).
The deletion of p53 alone resulted in an increase in
intracellular cAMP and phosphorylation of Creb1 (Fig. 1f,
g). We tested if overexpression of p53 could suppress the
cAMP-Creb1 axis. Primary osteoblasts were infected with
lentivirus overexpressing murine p53 (Fig. 2j, k). Down-
stream transcriptional targets of p53 were signiﬁcantly
increased in expression (Fig. 2k) and, strikingly, Creb1
targets were repressed (Fig. 2k). This result was conﬁrmed
independently in HEK293T cells overexpressing human
P53 (Supplemental Fig. 2C, D). The overexpression of p53
also led to a profound reduction in intracellular cAMP
formation in the cells (Fig. 2l), and a reduction of Creb1
phosphorylation (Fig. 2j). Thus, overexpression of p53
repressed cAMP accumulation and reduced Creb1
activity.
Accumulation of cAMP in p53-deﬁcient cells activates
proliferative networks
WT cells and isogenic KO counterparts were treated
with DMSO (control) or 100 μM IBMX for 1 h and the
expression/activation of the downstream cAMP-PKA
pathway monitored. Analysis of independently derived
cell cultures revealed increased levels of the PKA-catalytic
subunit and phospho-Creb1 in KO cells. There was a
basal activation of phospho-Creb1 in p53 KO cells as
compared to p53 WT cells (Fig. 3a).
To conﬁrm that the cAMP accumulated following
IBMX treatment, as seen in Fig. 1f, resulted in activation
of signaling qRT-PCRs were performed. The deletion of
p53 resulted in an expected decreased expression of Tp53
and p53 target genes (Fig. 3b, Supplemental Figure 3A)
and was associated with activation of Creb1 target genes
as we previously described7,8 (Fig. 3c, Supplemental
Fig. 3B). Loss of p53 was associated with an increased
expression of Ras and Myc45,46. To address this ﬁnding,
we selected several targets known to be regulated by Myc
and Ras47,48. Transcriptional target genes of both Myc and
Ras were signiﬁcantly upregulated in p53 KO cells
(Fig. 3d, Supplemental Figure 3C). In human OS, muta-
tions in components of the cAMP pathway have been
deﬁned, including in the PDE family, A kinase anchoring
proteins (AKAP) and protein phosphatases (PP)1. We
tested whether loss of p53 directly affected the expression
of these genes in WT and KO osteoblasts. The majority of
genes were not different between the genotypes, apart
from a complete loss of Pde4d mRNA in p53 KO cells
(Fig. 3e, Supplemental Fig. 3D). Pde4d hydrolyzes cAMP
and results in its breakdown49. Expression of markers of
osteoblast differentiation were upregulated in p53 KO
cells compared to the isogenic counterpart (Fig. 3f, Sup-
plemental Fig. 3E).
Activation of p53 directly suppresses Creb1
We next asked if genome-wide gene signatures asso-
ciated with cAMP-PKA were impacted by loss of p53 in
silico. Creb1 and P53 target genes were identiﬁed from
ChIP-seq studies39,41. The P53 target genes were further
reﬁned against a second independent dataset of p53 ChIP-
seq from murine embryonic ﬁbroblasts42. When over-
lapped, ~37% of Creb1 targets could also be directly
regulated by p53 (Fig. 4a). Of the common p53-Creb1
targets, the genes were then separated into groups that
were either up (n= 314) or down (n= 301) regulated by
p53, respectively, and pathway analysis performed using
DAVID50 (Fig. 4b). The functions of the genes repressed
by p53 were over-represented in pathways related to
protein kinase signaling (Fig. 4c), whereas the genes that
could be upregulated by p53 were associated with classical
p53 signatures including cell cycle arrest and apoptosis
(Fig. 4d).
To directly test the link between p53 and protein kinase
signaling we used a pharmacogenetic approach to exam-
ine how these pathways interacted when activated
(see ﬁgure on previous page)
Fig. 2 cAMP-induced apoptosis in normal osteoblast is negatively regulated by p53. a p53WT/WT and p53KO/KO cells treated with 1 mM IBMX;
representative image of 3 independent isogenic cells. b AnnexinV/7-AAD proﬁles of IBMX-treated p53WT/WT and p53KO/KO . c Percent apoptotic cells in
each culture p53WT/WT and p53KO/KO post-IBMX treatment (mean ± SEM, n= 3). d Apoptosis shown by cleaved caspase-3 activation in 3 independent
p53WT/WT and p53KO/KO isogenic cells. e Annexin V and 7AAD proﬁles of forskolin-treated p53WT/WT primary osteoblasts cells. f Percent apoptotic cells
in each culture p53WT/WT pre- and post-forskolin treatment (mean ± SEM, n= 3). g Western blot of phospho-p53, phospho-Creb1 with β-Actin as a
loading control. Data representative of 2 independent cell lines from each. h AnnexinV and 7AAD proﬁles of forskolin-treated p53WT/WT and p53KO/KO
primary osteoblasts cells. i Presence of cleaved caspase-3 in 3 independent p53WT/WT and p53KO/KO isogenic cells. j Western blot of p53, phospho-
Creb1 with β-Actin as a loading control. Data representative of 2 independent cell lines from each. k mRNA for p53, Cdkn1a1, Atp9a1, Mdm2, Creb1,
Nr4a1, Nr4a2, Nr4a3 by qPCR in p53WT/W cells at 72 h after overexpression of p53. Expression levels normalized to β2m; mean ± SEM (n= 3). l
Intracellular cAMP accumulation (pmol/µg protein; cells treated with 100 μM IBMX for 30 mins) in p53WT/WT cells overexpressed with p53; data pooled
from 3 independent cultures; mean ± SEM. For all panels: *P < 0.05, **P < 0.01, ***P < 0.001
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individually or concurrently. WT osteoblasts were treated
with the MDM2 inhibitor Nutlin-3a to activate WT p53
in a time course of 24 h. qRT-PCR demonstrated a sig-
niﬁcant activation of p53 target genes in a temporal
fashion (Fig. 5a). There was a reciprocal relationship
between p53 activation and the expression of Creb1 target
genes (Fig. 5b). The downregulation of Creb1 activity was
an early consequence of p53 activation, as Creb1 targets
were signiﬁcantly repressed with 2 h of Nutlin-3a treat-
ment (Fig. 5c, d). Similar inhibition of Creb1 activity
occurred when p53 was activated using doxorubicin, a
genotoxic drug used to treat a number of cancer including
OS (Supplemental Fig. 4A–C). Western blot analysis
conﬁrmed the increase in p53 by Nutlin-3a treatment in
p53 WT cells (Fig. 5e). In assessing this further, Nutlin-3a
mediated activation of p53 signiﬁcantly decreased
(see ﬁgure on previous page)
Fig. 3 Accumulation of cAMP in p53KO/KO cells leads to activation of pro-proliferative signatures. a Western blot of p53, phospho-Creb1 and
Creb1, PKA (catalytic subunit); β-Actin as loading control. Data representative of three independent isolates of isogenic p53WT/WT and p53KO/KO. Cells
were treated with 1 mM IBMX as indicated in methods. b Heat map of qPCR data. Expression of the p53 target genes between indicated cell types;
three independent isogenic cell lines for each, expressed as mRNA normalized to β2m. c Heat map of qPCR data. Expression of Creb1 target genes
between indicated cell types; > 3 independent isogenic cell lines for each, expressed as mRNA normalized to β2m. d Heat map of qPCR data for
genes important in cellular proliferation. Expression of the Creb1 target genes between indicated cell types.; > 3 independent isogenic cell lines for
each, expressed as mRNA normalized to β2m. e Heat map of qPCR data for genes that are negative regulators of cAMP. Expression of the genes
between indicated cell types; three independent isogenic cell lines for each, expressed as mRNA normalized to β2m. f Heat map of qPCR data for
genes important in development. Expression of the genes between indicated cell types; > 3 independent isogenic cell lines for each, expressed as
mRNA normalized to β2m. Data pooled from 3 independent cultures; mean ± SEM. See Figure S3. For all panels: *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4 In silico analysis of p53 and Creb chromatin targets. a Venn diagram depicting the overlap and outliers between common human and
mouse p53 targets and Creb1 ChIP-seq dataset. b Table showing the bifurcation of up- and downregulated Creb1 targets regulated by p53. c
Pathways governed by p53-mediated downregulated Creb1 targets. d Pathways governed by p53-mediated upregulation of Creb1 targets
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intracellular cAMP levels in WT osteoblasts and this
effect was completely prevented in KO cells (Fig. 5f). The
activation of p53 therefore leads to reduced formation of
intracellular cAMP and a repression of Creb1 transcrip-
tional activity.
Simultaneous p53 activation and elevated cAMP levels
induce apoptosis
In order to determine whether elevated intracellular
cAMP can directly affect the cells’ response to p53 acti-
vation, we treated WT and KO osteoblasts with Nutlin-3a
alone (p53 activator), forskolin alone (cAMP stimulus)
or the combination of both for 24 h and evaluated the
cellular effects and gene expression. Elevating cAMP
together with activation of p53 led to apoptosis in
p53 WT osteoblasts. qRT-PCR was performed revealing
that simultaneous activation of p53 and cAMP resulted
in the suppression of Creb1 targets, suggesting that
the response by p53 was dominant over the cAMP-
induced response (Fig. 6a, b). There was no signiﬁcant
effect on the expression of genes important for osteo-
blastic lineage development such as Osterix and Runx2
(Supplemental Fig. 5A). This effect was rapid, seen
within 1 h. The transcriptional effect of p53 activation
and Creb1 signature suppression was absent in p53 KO
cells, which conﬁrmed the speciﬁcity of this response
to p53 (Fig. 6c). A comparable effect was observed
when doxorubicin was combined with forskolin, with
the cells undergoing apoptosis and Creb1 target genes
being suppressed (Fig. 6d–f, Supplemental Fig. 5B). PI
staining was performed to assess the cell cycle status
of the cells and there was no signiﬁcant change in cell
cycle parameters (Supplemental Fig. 5C), suggesting that
at least in the window of treatment there was no obvious
changes in cell cycle parameters. This indicates that
the ability to tolerate elevated and aberrant cAMP path-
way activation in osteoblasts, as is seen in OS, is dictated
by p53 status.
Creb1, Cbp, and p53 can occur in complex
Phosphorylation of CREB mediates recruitment of
co-activator associated complex of Creb1 (CBP) to
p53-responsive promoters, through potentially a direct
interaction with p5336. In whole cell lysates from p53 WT
and KO cells, steady state Creb1 and phospho-Creb1 were
signiﬁcantly higher (Figs. 1, 2). To assess if there was a
direct interaction between p53 and Creb1, Creb1 was
immunoprecipitated and the Creb1-containing complexes
from p53 WT cells assessed with p53 KO cells used as a
control. In the WT cells, p53 was co-immunoprecipitated
with both Creb1 and phospho-Creb1-containing protein
complexes (Fig. 7a). We assessed whether Cbp was also
associated with Creb1 complexes in these cells. When
Creb1 was immunoprecipitated in both cell types, it could
be found associated with Cbp (Fig. 7b). Interestingly,
when Cbp containing complexes were immunoprecipi-
tated from p53 WT and KO cells, it revealed a different
interaction. In the presence of p53, Cbp could interact
with p53, but there was greatly reduced interaction with
Creb1 (Fig. 7a). However, with the loss of p53 there was
enhanced interaction of Creb1 with Cbp (Fig. 7b). Whilst
the consequences of this are not immediately clear, they
suggest that p53 status may regulate the extent of inter-
action of Creb1 and Cbp.
We further sought to understand how the dynamics of
the p53-Creb1-Cbp interactions changed in response to
activation of p53 or cAMP. WT and KO cells were treated
with DMSO, Nutlin-3a, forskolin, or forskolin/Nutlin-3a
followed by immunoprecipitation with p53. Following
p53 activation there was a decreased amount of Creb1
associated with p53 (Fig. 7c). When cAMP levels
were increased in isolation of p53 activation, there was
evidence of the p53-Creb1-Cbp interaction, however
there was less p53 associated with this complex. When
both p53 and cAMP pathways were activated con-
currently, the strongest association between these pro-
teins could be seen.
Inhibition of the Creb1-Cbp interaction as a potential
therapeutic strategy for osteosarcoma
Several new chemical inhibitors of the CREB pathway
have been described, including the CREB inhibitor
666–1551. We tested 666–15 against normal osteoblasts
(p53+/+), primary p53 KO osteoblasts and primary OS
cell cultures isolated from both ﬁbroblastic and osteo-
blastic OS mouse models16,22. A dose response assay
(see ﬁgure on previous page)
Fig. 5 Activation of p53 directly suppresses Creb1 function. a qPCR validation of p53 target gene expression following 10 μM Nutlin treatment
over time course of 24 h; 3 independent isogenic p53WT/WT cells, mean ± SEM. b qPCR validation of Creb1 target gene expression following 10 μM
Nutlin treatment over time course of 24 h; 3 independent isogenic p53WT/WT cells, mean ± SEM. c qPCR validation of p53 target gene expression
following 10 μM Nutlin treatment over time course of 2 h; 3 independent isogenic p53WT/WT cells, mean ± SEM. d qPCR validation of Creb1 target
gene expression following 10 μM Nutlin treatment over time course of 2 h; 3 independent isogenic p53WT/WT cells, mean ± SEM. e Western blot of
p53, Phospho-Creb1 and Creb1 post-Nutlin-3a treatment for time course of 2 h; β-Actin used as a loading control; Data representative of 2
independent isogenic cell lines. f Intracellular cAMP formation (pmol/μg protein) in p53WT/WT and p53KO/KO (IBMX 100 μM) 30mins post-Nutlin
treatment; data pooled from 3 independent cultures; mean ± SEM. See ﬁgure S4. For all panels: *P < 0.05, **P < 0.01, ***P < 0.001
Walia et al. Cell Death and Disease  (2018) 9:844 Page 12 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 6 (See legend on next page.)
Walia et al. Cell Death and Disease  (2018) 9:844 Page 13 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
demonstrated genotype dependent toxicity after 48 h,
which was speciﬁc for p53 KO osteoblastic cells and the
p53 null OS (Fig. 8a). Normal osteoblasts tolerated high
doses of 666–15, unlike OS cells and p53-deﬁcient
osteoblasts. Incubating the cells for 72 h with 666–15
led to a more pronounced effect on the OS cells (Fig. 8b).
We therefore determined how the cells were dying by
measuring the levels of cleaved caspase-3. Inhibition of
Creb1-Cbp interaction led to apoptosis in the OS cells but
not in normal osteoblasts (Fig. 8c). This result suggested
that the Creb1-Cbp interaction is required for the main-
tenance of proliferation of p53-deﬁcient osteoblasts and,
more importantly, the viability of OS cells.
Discussion
P53 is a negative regulator of key cell fate-mediated
programs which, when perturbed, can lead to tumor
formation7,16,20–22,52. OS, unlike most tumor types, fre-
quently harbors null alleles of TRP531,3. The reason for
this mutational preference in osteoblastic cells, the lineage
of origin of OS22, is not clear. Evidence for elevated and
persistent signalling through the cAMP/PKA axis in OS
has come from mouse genetic models, including those we
have developed6–9, as well as from mutational analysis of
human OS1, all leading to the view that deregulation of
this pathway plays a critical role in OS6–8. In the present
work, we have studied the nexus between p53 and cAMP
pathways in normal osteoblastic cells. Persistently ele-
vated cAMP levels induce cellular stress in osteoblastic
cells, and p53 counteracts this by inducing apoptosis
(Fig. 8d). In the absence of p53, a state sufﬁcient to initiate
OS, osteoblastic cells become tolerant to elevated and
otherwise toxic levels of cAMP/Creb1 pathway activity
(Fig. 8d).
We have utilized a reductionist cellular model to
understand the consequences of the key mutation in OS,
p53 loss, in primary osteoblasts. In this model there was a
coordinated increase in cAMP and activated Creb1 levels
and transcriptional activity as osteoblastic cells became
p53-deﬁcient, prior to transformation into OS. In addi-
tion, there was increased expression of Pthlh and PTHrP,
which we have shown previously to be a critical autocrine
(see ﬁgure on previous page)
Fig. 6 Concurrent activation of p53 and cAMP pathway leads to apoptosis. a AnnexinV/7-AAD proﬁles of p53WT/WT cells treated with less than
0.1% DMSO, 10 μM Nutlin, 10 μM Forskolin, and combined treatment with Forskolin and Nutlin. b Percent apoptotic cells in each treatment group;
mean ± SEM. c Heat map of qPCR data. Expression of the p53 and Creb1/pro-proliferative targets, developmental targets between cell types; Data
from 3 independent isogenic cell lines for each, expressed as relative expression normalized to β2m. Data expressed as mean ± SEM (n= 3).
d AnnexinV/7-AAD proﬁles of p53WT/WT cells treated with less than 0.1% DMSO, 500 nM Doxorubicin, 10 μM Forskolin and combinatorial treatment of
Forskolin and Doxorubicin. e Percent apoptotic cells in each treatment group; 3 independent cell lines. f Heat map of qPCR data. Expression of the
p53 and Creb1/pro-proliferative targets, developmental targets between cell types; Data from 3 independent isogenic cell lines for each, expressed
as relative expression normalized to β2m. Data expressed as mean ± SEM (n= 3). For all panels: *P < 0.05, **P < 0.01, ***P < 0.001. See ﬁgure S5.
For all panels: *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 7 Creb1, Cbp, and p53 interact. a Western blot following immunoprecipitation of Creb1 and immunoblot with Cbp, p53 and Creb1 from 3
independent isogenic p53WT/WT and p53KO/KO. b Western blot following Cbp immunoprecipitation and immunoblot with Cbp, p53, and Creb1 from
3 independent isogenic p53WT/WT and p53KO/KO. c Western blot analysis of p53 immunoprecipitation and immunoblot with Cbp, p53, Creb1, and
phospho-Creb1 from isogenic p53WT/WT and p53KO/KO cells treated with DMSO, Nutlin, Forskolin, and Forskolin+ Nutlin
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stimulus of the cAMP-Creb1 pathway in OS6–8. When
WT primary osteoblasts were prompted to undergo
osteogenic differentiation in culture, p53 and Creb1
expression declined during differentiation. However,
in p53 KO primary osteoblasts, the decrease in Creb1
expression during differentiation was delayed. The loss of
p53 thus induces an aberrant differentiation program and
depresses the cAMP pathway in osteoblasts.
Undifferentiated osteoblastic cells expressed PTHrP
but have low to undetectable levels of PTHR1. In normal
osteoblast lineage cells, immature osteoblasts make
PTHrP but do not sense it, instead it acts in a paracrine
manner on more mature osteoblastic lineage cells10,14.
However, in OS we previously reported that OS cells
make PTHrP and have functional PTHR1, with an auto-
crine axis maintaining elevated and persistent
Fig. 8 Inhibiting the interaction of Creb1-Cbp leads to toxicity in p53 null osteosarcoma cells. a Dose response curves of cells treated with
666–15 Creb1-Cbp inhibitor for 48 h. b Dose response curves of cells treated with 666–15 Creb1-Cbp inhibitor for 72 h. c Western blot analysis for
cleaved caspase-3 from the indicated cells treated for 48 h with the Creb1-Cbp interaction inhibitor 666–15. d Graphical summary of the differences
between lineages committed pre-osteoblasts and the sequence of expression of paracrine action of PTHrP on differentiating cells expressing PTHR1.
Pre-osteoblasts cannot tolerate increased cAMP levels as compared to p53-deﬁcient osteosarcoma cells
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intracellular cAMP levels in OS (Fig. 8d)6,8. To investigate
the consequence of maximal accumulation of cAMP in
osteoblastic cells, we treated cells with either IBMX
(prevents breakdown of cAMP) or used forskolin (directly
elevates intracellular cAMP). This demonstrated that
excessive intracellular cAMP was poorly tolerated by
normal osteoblastic cells, resulting in apoptosis. The loss
of p53 was sufﬁcient to enable the cells to survive and
tolerate the increased cAMP levels. Strikingly, over-
expression of p53 in osteoblastic cells was able to reduce
intracellular cAMP formation and subsequent activation
of the cAMP-Creb1 pathway. We assessed the interaction
of these pathways in WT osteoblasts by simultaneously
treating cells with forskolin and Nutlin-3a, alone or in
combination. p53 activation (Nutlin-3a) is sufﬁcient to
repress downstream target gene activation within the
cAMP pathway. Our data indicate that osteoblastic cells
do not normally tolerate sustained elevations of intracel-
lular cAMP. Loss of p53 imparts an advantage to osteo-
blasts to tolerate accumulated cAMP levels. Increased
expression/activity of the cAMP-Creb pathway is an early
event following p53 loss in osteoblasts. Thus, abrogation
of p53 activity is necessary before cells can tolerate ele-
vated cAMP pathway activity and utilize it for tumor
initiation. Our data also indicate that OS cells tolerate
elevated cAMP levels due to the abrogation of the p53-
dependent apoptotic response that normal osteoblastic
cells incur following activation of this pathway.
Restoration of p53 tumor suppressor pathway function
is a promising anti-cancer strategy53. However, such
approaches are not feasible in p53 null settings such as
OS. New treatment options for OS are sorely needed, with
the advances in patient outcome over the last 30 years
coming from optimizing application of existing therapies
rather than the introduction of new agents. The rapid
activation of the cAMP pathway following p53 deletion,
and its persistence and ampliﬁcation in OS, may highlight
a therapeutic vulnerability in OS cells. We identiﬁed that
p53 can interact with Creb1 and its co-activator Cbp. Loss
of p53 increased the association of Creb1 with Cbp, fur-
ther enhancing the cellular reprogramming by enabling
the elevated cAMP levels to be reﬂected transcriptionally.
Based on these ﬁndings, we explored the option of inhi-
biting the Creb1-Cbp complex interaction. We used an
inhibitor, 666–15, which acts by blocking the interaction
of CREB1 with CBP51. 666–15 or its preceding com-
pounds have demonstrated preclinical efﬁcacy in vivo in
leukemia models54. Strikingly, inhibition of the Creb1-
Cbp interaction had a selective effect on p53 null cells,
with a graded response of increasing sensitivity as cells
transition from p53-deﬁcient osteoblasts to OS, sparing
normal osteoblasts. This result demonstrates that sus-
tained Creb1-Cbp activity is required for survival of
OS cells. Collectively our results demonstrate a close
relationship between loss of p53 and tolerance to elevated
and persistent cAMP/Creb1 signaling in osteoblasts.
These pathways are central to the biology of OS and here
we ﬁnd that they are coupled from the earliest events in
the initiation of this tumor. Importantly, our results also
demonstrate that this pathway may be therapeutic vul-
nerable in p53-deﬁcient tumors such as OS.
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